Ovarian Cancer

Multiple dose gene therapy yields best results in recurrent ovarian cancer

Published in Gene Therapy Weekly, July 25th, 2002

by Sonia Nichols, senior medical writer - Long-term evaluations of ovarian cancer patients treated with p53 gene replacement therapy in a phase I/II clinical trial indicate the therapy is more effective when administered in multiple doses.

Members of an international research team have issued the results of using a p53 gene replacement therapy known as SCH 58500 to treat women with recurrent ovarian cancer in a set of reports published in the July 2002 issue of Cancer Gene Therapy. According to these investigators, long-term follow-up of treated patients suggests that multiple doses of the therapy tends to extend survival better than single-dose therapy does in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-07-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry